Abstract
Background: Rearranged during transfection (RET), a transmembrane receptor tyrosine kinase, is involved in multi-system tissue development which includes nervous, hematopoietic, and gastrointestinal systems. Activating RET alteration, induced by gene fusions or point mutations, has been discovered in several different solid tumor types including thyroid cancer, non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Recently, two RET-specific tyrosine kinase inhibitors (TKIs), selpercatinib (LOXO-292) and pralsetinib (BLU-667), were approved by the FDA for the treatment of thyroid cancer and NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
